Clinical trials: GASTROINTESTINAL NEOPLASMS
Pancreatic Cancer
Bevacizumab and Erlotinib in Treating Patients With Metastatic Pancreatic Cancer That Did Not Respond to Previous Treatment With Gemcitabine
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00365144
- Testing
- bevacizumab, erlotinib hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of California, San Francisco
Pancreas Cancer
Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer
The purpose of this research is to determine the benefit of two oral chemotherapy drugs, Vemurafenib and Sorafenib, in individuals with KRAS mutated pancreatic cancer who have progressed on standard chemotherapy.
- Trial name
- NCT05068752
- Testing
- Vemurafenib, Sorafenib
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- HonorHealth Research Institute
Colorectal Cancer
An Evaluation of a Multi-target Stool DNA (Mt-sDNA) Test, Cologuard, for CRC Screening in Individuals Aged 45-49 and at Average Risk for Development of Colorectal Cancer: Act Now
The primary objective is to confirm the specificity of a multi-target stool DNA test (mt-sDNA), Cologuard, in an average risk population, ages 45-49.
- Trial name
- NCT03728348
- Testing
- mt-sDNA screening test, Colonoscopy
- Where
- 39 sites in United States
- Volunteers
- 983 people, healthy volunteers welcome
- Sponsor
- Exact Sciences Corporation
Recurrent Colon Cancer, Recurrent Rectal Cancer
SB-715992 in Treating Patients With Advanced or Metastatic Colorectal Cancer
This randomized phase II trial is studying how well SB-715992 works in treating patients with advanced or metastatic colorectal cancer.
- Conditions
- Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IIIA Colon Cancer, Stage IIIA Rectal Cancer
- Trial name
- NCT00103311
- Testing
- ispinesib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- National Cancer Institute (NCI)
Colo-rectal Cancer
The United States Healthy Living Study
The purpose of this study is to pilot test the efficacy of a patient-centered, tailored message intervention delivered via virtual human technology for increasing colorectal cancer (CRC) screening within guidelines.
- Trial name
- NCT03867409
- Testing
- message delivered via virtual technology
- Where
- United States
- Volunteers
- 2,105 people, healthy volunteers welcome
- Sponsor
- University of Florida
Colorectal Carcinoma
Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164)
In this study, participants with previously-treated locally-advanced unresectable or metastatic mismatched repair (MMR) deficient or microsatellite instability-high (MSI-H) colorectal carcinoma (CRC) will be treated with…
- Trial name
- NCT02460198
- Testing
- Pembrolizumab
- Volunteers
- 124 people
- Sponsor
- Merck Sharp & Dohme LLC
Dysphagia, Oral Pharyngeal Cancer
Pilot Study to Improve Therapeutic Outcomes for Dysphagia After Radiation Therapy
Patients with head and neck cancer treated with chemoradiation, often develop a treatment associated dysphagia. The common complaint is foods sticking in the pharynx.
- Trial name
- NCT02564887
- Testing
- Iowa Oral Performance Instrument
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Jonas Johnson
Colon Cancer, Rectal Cancer
A Study of Ramucirumab or Icrucumab in Colorectal Cancer
The purpose of this study is to determine if participants with metastatic colorectal cancer live longer without their cancer progressing when treated with standard chemotherapy, standard chemotherapy plus ramucirumab, or standard…
- Trial name
- NCT01111604
- Testing
- Ramucirumab, Icrucumab, mFOLFOX-6
- Where
- 17 sites in United States, Canada
- Volunteers
- 158 people
- Sponsor
- Eli Lilly and Company
Neoplasms, Colorectal
Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced Colorectal Cancer
The purpose of this study is to determine the highest, tolerated dose level and safety of lapatinib, capecitabine and oxaliplatin in subjects with advanced cancer and to determine the clinical activity of the combination of drugs…
- Trial name
- NCT00536809
- Testing
- lapatinib, oxaliplatin, capecitabine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- GlaxoSmithKline
Pancreatic Cancer
Capecitabine, Docetaxel and Gemcitabine in Patients With Advanced Pancreas Cancer
The primary purpose of this study is to define the maximum tolerated dose of combination docetaxel, gemcitabine, and capecitabine in patients with pancreatic cancer. Adverse effects will be measured in study participants.
- Trial name
- NCT00320749
- Testing
- Capecitabine, Docetaxel, Gemcitabine
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Tony Bekaii-Saab
Metastatic Pancreatic Ductal Adenocarcinoma
Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
This is a Phase 3, open-label study to evaluate the objective response rate (ORR), in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with relacorilant in combination with nab-paclitaxel, according to…
- Trial name
- RELIANT (NCT04329949)
- Testing
- Relacorilant, 100 mg and 25 mg, Nab-paclitaxel
- Where
- 18 sites in United States
- Volunteers
- 43 people
- Sponsor
- Corcept Therapeutics
Unresectable or Metastatic Microsatellite Stable (MSS) Solid Tumor, Microsatellite Stable (MSS) Colon Cancer
Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer
A phase I/II study of PI3Kinase inhibition (copanlisib) and anti-PD-1 antibody nivolumab in relapsed/refractory solid tumors with expansions in mismatch-repair proficient (MSS) colorectal cancer.
- Trial name
- NCT03711058
- Testing
- Copanlisib, Nivolumab
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas
Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer
This partially randomized phase Ib/II trial studies the side effects and best dose of selinexor when given together with gemcitabine and nab-paclitaxel, and to see how well they work in treating patients with pancreatic cancer…
- Conditions
- Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Stage IV Pancreatic Cancer
- Trial name
- NCT02178436
- Testing
- gemcitabine hydrochloride, Selinexor, Pharmacological Study
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Mohammed Najeeb Al Hallak
Small Cell Lung Carcinoma, Non Small Cell Lung Carcinoma
Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients
The purpose of this study is to determine a well-tolerated dose of Carfilzomib in combination with Irinotecan (Phase 1b portion of the study) in subjects with relapsed small and non-small cell lung cancer or other…
- Conditions
- Small Cell Lung Carcinoma, Non Small Cell Lung Carcinoma, Irinotecan Sensitive Cancers
- Trial name
- NCT01941316
- Testing
- Carfilzomib, Irinotecan
- Where
- 8 sites in United States
- Volunteers
- 78 people
- Sponsor
- Cancer Research and Biostatistics Clinical Trials Consortium
Colorectal Cancer
Polyp Measurement Device
Colorectal cancer is the second-leading cause of cancer death in the United States. Colorectal cancer screening is recommended to begin at age 50 years for most men and women at average risk for this disease.
- Trial name
- NCT03856255
- Testing
- Micro-Tech Endoscopic Gauge
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Carcinoma, Hepatocellular
Proton Radiotherapy Plus Sorafenib Versus Sorafenib for Patients With HCC Exceeding San Francisco Criteria
This study is designed to determine whether proton beam radiotherapy plus Sorafenib compared to Sorafenib alone will produce the best results for treating patients with Hepatocellular Carcinoma.
- Trial name
- HCC (NCT01141478)
- Testing
- Proton Beam Radiotherapy, Sorafenib
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Loma Linda University
Carcinoma
Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.
The purpose of this study is to compare treatment with RAD001 plus best supportive care (BSC) to placebo plus BSC in patients with advanced HCC whose disease progressed while on or after sorafenib treatment or who are intolerant…
- Trial name
- EVOLVE-1 (NCT01035229)
- Testing
- Everolimus, Best Supportive Care (BSC)
- Where
- 131 sites in United States, Australia and 16 more
- Volunteers
- 546 people
- Sponsor
- Novartis Pharmaceuticals
Esophageal Cancer
A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma
The purpose of this study is to evaluate the efficacy and safety of atezolizumab plus tiragolumab in combination with paclitaxel and cisplatin (PC) compared with atezolizumab matching placebo plus tiragolumab matching placebo…
- Trial name
- SKYSCRAPER-08 (NCT04540211)
- Testing
- Atezolizumab, Tiragolumab, Paclitaxel
- Where
- 67 sites in China, Hong Kong and 3 more
- Volunteers
- 461 people
- Sponsor
- Hoffmann-La Roche
Esophageal Squamous Cell Carcinoma
Adjuvant Pembrolizumab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma at High Risk of Recurrence
In this study, participants with histologically diagnosed locally advanced esophageal squamous cell carcinoma who have received preoperative cisplatin-based chemoradiotherapy followed by surgery harbouring high risk of tumor…
- Trial name
- NCT03322267
- Testing
- Pembrolizumab
- Where
- Taiwan
- Volunteers
- 26 people
- Sponsor
- National Taiwan University Hospital
Medullary Thyroid Cancer, Infantile Myofibromatosis
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
This is an open-label, multi-center Phase 1/2 study of oral LOXO-292 in pediatric participants with an activating rearranged during transfection (RET) alteration and an advanced solid or primary CNS tumor.
- Conditions
- Medullary Thyroid Cancer, Infantile Myofibromatosis, Infantile Fibrosarcoma, Papillary Thyroid Cancer
- Trial name
- LIBRETTO-121 (NCT03899792)
- Testing
- Selpercatinib
- Where
- 26 sites in United States, Australia and 9 more
- Volunteers
- 36 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.